# Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

> **NCT00097786** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9306 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Valsartan 160 mg + nateglinide 60 mg
- **DRUG:** Valsartan 160 mg + nateglinide placebo
- **DRUG:** Nateglinide 60 mg + valsartan placebo
- **DRUG:** Valsartan placebo + nateglinide placebo

## Key facts

- **NCT ID:** NCT00097786
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 9306 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097786, "Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00097786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*